Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

889 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study.
Saleheen D, Scott R, Javad S, Zhao W, Rodrigues A, Picataggi A, Lukmanova D, Mucksavage ML, Luben R, Billheimer J, Kastelein JJ, Boekholdt SM, Khaw KT, Wareham N, Rader DJ. Saleheen D, et al. Among authors: kastelein jj. Lancet Diabetes Endocrinol. 2015 Jul;3(7):507-13. doi: 10.1016/S2213-8587(15)00126-6. Epub 2015 May 27. Lancet Diabetes Endocrinol. 2015. PMID: 26025389 Free PMC article.
Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events.
Boekholdt SM, Agema WR, Peters RJ, Zwinderman AH, van der Wall EE, Reitsma PH, Kastelein JJ, Jukema JW; REgression GRowth Evaluation Statin Study Group. Boekholdt SM, et al. Among authors: kastelein jj. Circulation. 2003 May 20;107(19):2416-21. doi: 10.1161/01.CIR.0000068311.40161.28. Epub 2003 May 12. Circulation. 2003. PMID: 12742999 Clinical Trial.
The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the cholesterol and recurrent events study: no interaction with the response to pravastatin therapy and no effects on cardiovascular outcome: a prospective analysis of the CETP TaqIB polymorphism on cardiovascular outcome and interaction with cholesterol-lowering therapy.
de Grooth GJ, Zerba KE, Huang SP, Tsuchihashi Z, Kirchgessner T, Belder R, Vishnupad P, Hu B, Klerkx AH, Zwinderman AH, Jukema JW, Sacks FM, Kastelein JJ, Kuivenhoven JA. de Grooth GJ, et al. Among authors: kastelein jj. J Am Coll Cardiol. 2004 Mar 3;43(5):854-7. doi: 10.1016/j.jacc.2003.08.056. J Am Coll Cardiol. 2004. PMID: 14998629 Free article.
889 results